Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Nov 9;16(1):42–53. doi: 10.1002/1878-0261.13087

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published 2021. This article is a U.S. Government work and is in the public domain in the USA. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1 — mBCRS correlations with 313 SNP PRS and age and mBCRS distributions in the Sister Study testing set. Among women sampled as part of the random subcohort and selected into the testing set (n = 375), scatterplot and fit line between mBCRS values and the 313 SNP PRS (Pearson’s correlation: 0.03, top left panel); and scatterplot and fit line between mBCRS and age at blood draw (Pearson’s correlation: 0.09, top right panel). The distribution of mBCRS on the original scale ranged from 44.28 to 45.96, with a mean of 45.20 (SD = 0.19); women who remained cancer‐free had a mean of 45.14 (SD = 0.17), those who developed breast cancer had a mean of 45.24 (SD = 0.20) (bottom left panel). The standardized residuals for mBCRS ranged from −5.30 to 5.20, with a mean of 0.30 (SD = 1.19); women who remained cancer‐free had a mean of −0.03 (SD = 0.99), and those who developed breast cancer had a mean of 0.56 (SD = 1.27) (bottom right panel).